Epizyme (EPZM) Issues Encouraging Update on EPZ-6438 Phase 1 in Adv. B-Cell NHL
Tweet Send to a Friend
Epizyme (NASDAQ: EPZM) reported results from the ongoing phase 1 trial of tazemetostat (EPZ-6438), a first-in-class EZH2 inhibitor, showing meaningful ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
